A critical role of c-Cbl-interacting protein of 85 kDa in the development and progression of head and neck squamous cell carcinomas through the Ras-ERK pathway

Neoplasia

Volumn 12, Issue 10, 2010, Pages 789-796

  Wakasaki, Takahiro ^a   Masuda, Muneyuki ^b   Niiro, Hiroaki ^a   Jabbarzadeh Tabrizi, Siamak ^a   Noda, Kumiko ^a   Taniyama, Tadayoshi ^c   Komune, Shizuo ^a   Akashi, Koichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Kyushu Koseinennkin Hospital   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; C CBL INTERACTING PROTEIN 85; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MYC PROTEIN; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA;

EID: 77957823973     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10396     Document Type: Article

References (30)

1. Bernier J, Bentzen SM, and Vermorken JB (2009). Molecular therapy in head and neck oncology. Nat Rev Clin Oncol 6, 266-277.
2. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, and Tweardy DJ (1998). Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90, 824-832.
3. Ongkeko WM, Altuna X, Weisman RA, and Wang-Rodriguez J, (2005). Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am J Clin Pathol 124, 71-76.
4. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Rosello J, Nicholson RI, et al. (2001). Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61, 6500-6510.
5. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, Tomita K, Komiyama S, and Weinstein IB, (2002). Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 62, 3351-3355.
6. Masuda M, Ruan HY, Ito A, Nakashima T, Toh S, Wakasaki T, Yasumatsu R, Kutratomi Y, Komune S, and Weinstein IB (2007). Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma. Oral Oncol 43, 785-790.
7. Masuda M, Wakasaki T, Suzui M, Toh S, Joe AK, and Weinstein IB (2010). Stat3 orchestrates tumor development and progression: the Achilles' heel of head and neck cancers? Curr Cancer Drug Targets 10, 117-126.
8. Hoa M, Davis SL, Ames SJ, and Spanjaard RA (2002). Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma. Cancer Res 62, 7154-7156.
9. Take H, Watanabe S, Takeda K, Yu ZX, Iwata N, and Kajigaya S, (2000). Cloning and characterization of a novel adaptor protein, CIN85, that interacts with c-Cbl. Biochem Biophys Res Commun 268, 321-328.
10. Dikic I (2002). CIN85/CMS family of adaptor molecules. FEBS Lett 529, 110-115.
11. Havrylov S, Rzhepetskyy Y, Malinowska A, Drobot L, and Redowicz MJ (2009). Proteins recruited by SH3 domains of Ruk/CIN85 adaptor identified by LC-MS/MS. Proteome Sci 7, 21.
12. Sorkin A and Goh LK (2009). Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 315, 683-696.
13. Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, and Dikic I (2002). Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature 416, 183-187.
14. Narita T, Ando A, Mikami Y, and Taniyama T (2005). Overexpression of CIN85 suppresses the growth of herpes simplex virus in HeLa cells. Exp Cell Res 311, 265-271.
15. Tabrizi SJ, Niiro H, Masui M, Yoshimoto G, Iino T, Kikushige Y, Wakasaki T, Baba E, Shimoda S, Miyamoto T, et al. (2009). T cell leukemia/lymphoma 1 and galectin-1 regulate survival/cell death pathways in human naive and IgM+ memory B cells through altering balances in Bcl-2 family proteins. J Immunol 182, 1490-1499.
16. Vink SR, van der Luit AH, Klarenbeek JB, Verheij M, and van Blitterswijk WJ (2007). Lipid rafts and metabolic energy differentially determine uptake of anticancer alkylphospholipids in lymphoma versus carcinoma cells. Biochem Pharmacol 74, 1456-1465.
17. Akervall J, Bockmuhl U, Petersen I, Yang K, Carey TE, and Kurnit DM (2003). The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1: CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck. Clin Cancer Res 9, 1750-1755.
18. Massague J (2004). G1 cell-cycle control and cancer. Nature 432, 298-306.
19. Bogler O, Furnari FB, Kindler-Roehrborn A, Sykes VW, Yung R, Huang HJ, and Cavenee WK (2000). SETA: a novel SH3 domain-containing adapter molecule associated with malignancy in astrocytes. Neuro Oncol 2, 6-15.
20. Mayevska O, Shuvayeva H, Igumentseva N, Havrylov S, Basaraba O, Bobak Y, Barska M, Volod'ko N, Baranska J, Buchman V, et al. (2006). Expression of adaptor protein Ruk/CIN85 isoforms in cell lines of various tissue origins and human melanoma. Exp Oncol 28, 275-281.
21. Nam JM, Onodera Y, Mazaki Y, Miyoshi H, Hashimoto S, and Sabe H (2007). CIN85, a Cbl-interacting protein, is a component of AMAP1-mediated breast cancer invasion machinery. EMBO J 26, 647-656.
22. Pennock S and Wang Z (2003). Stimulation of cell proliferation by endosomal epidermal growth factor receptor as revealed through two distinct phases of signaling. Mol Cell Biol 23, 5803-5815.
23. Rotblat B, Yizhar O, Haklai R, Ashery U, and Kloog Y (2006). Ras and its signals diffuse through the cell on randomly moving nanoparticles. Cancer Res 66, 1974-1981.
24. Roepstorff K, Grandal MV, Henriksen L, Knudsen SL, Lerdrup M, Grovdal L, Willumsen BM, and van Deurs B (2009). Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic 10, 1115-1127.
25. Hecker TP, Ding Q, Rege TA, Hanks SK, and Gladson CL (2004). Overexpression of FAK promotes Ras activity through the formation of a FAK/p120RasGAP complex in malignant astrocytoma cells. Oncogene 23, 3962-3971.
26. Schmidt MH, Chen B, Randazzo LM, and Bogler O (2003). SETA/CIN85/Ruk and its binding partner AIP1 associate with diverse cytoskeletal elements, including FAKs, and modulate cell adhesion. J Cell Sci 116, 2845-2855.
27. Lito P, Mets BD, Kleff S, O'Reilly S, Maher VM, and McCormick JJ (2008). Evidence that sprouty 2 is necessary for sarcoma formation by H-Ras oncogenetransformed human fibroblasts. J Biol Chem 283, 2002-2009.
28. Dikic I and Giordano S (2003). Negative receptor signalling. Curr Opin Cell Biol 15, 128-135.
29. Tossidou I, Kardinal C, Peters I, Kriz W, Shaw A, Dikic I, Tkachuk S, Dumler I, Haller H, and Schiffer M, (2007). CD2AP/CIN85 balance determines receptor tyrosine kinase signaling response in podocytes. J Biol Chem 282, 7457-7464.
30. Grunkemeyer JA, Kwoh C, Huber TB, and Shaw AS (2005). CD2-associated protein (CD2AP) expression in podocytes rescues lethality of CD2AP deficiency. J Biol Chem 280, 29677-29681.